Trials / Conditions / Unresectable Metastatic Colorectal Cancer

Unresectable Metastatic Colorectal Cancer

12 registered clinical trials studyying Unresectable Metastatic Colorectal Cancer — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastat NCT06934538	Brenus Pharma	Phase 1 / Phase 2
Not Yet Recruiting	SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresect NCT06835179	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Not Yet Recruiting	Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment NCT06642844	University Hospital, Tours	Phase 3
Active Not Recruiting	Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receivi NCT06107413	AbbVie	Phase 2
Recruiting	Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First- NCT06148402	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2
Unknown	A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Co NCT04866108	Beijing Friendship Hospital	Phase 2
Recruiting	Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer NCT04991948	Celyad Oncology SA	Phase 1
Unknown	A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (Cape NCT05068206	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2
Unknown	Probiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Ca NCT04131803	Second Affiliated Hospital, School of Medicine, Zhejiang University	N/A
Unknown	mXELOXIRI Combined With Molecular Targeted Drug in mCRC NCT04160416	First Affiliated Hospital of Zhejiang University	Phase 2
Recruiting	alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Ant NCT03692429	Celyad Oncology SA	Phase 1
Completed	OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer NCT01802684	GERCOR - Multidisciplinary Oncology Cooperative Group	Phase 2